Delta Lloyd NV increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 18.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,569 shares of the company’s stock after buying an additional 5,579 shares during the period. Delta Lloyd NV’s holdings in Zoetis were worth $1,850,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. raised its stake in shares of Zoetis by 6.5% in the second quarter. Vanguard Group Inc. now owns 29,819,968 shares of the company’s stock worth $1,415,256,000 after buying an additional 1,812,428 shares during the last quarter. Independent Franchise Partners LLP raised its stake in shares of Zoetis by 1.6% in the third quarter. Independent Franchise Partners LLP now owns 11,361,033 shares of the company’s stock worth $590,887,000 after buying an additional 177,286 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Zoetis by 0.9% in the second quarter. Principal Financial Group Inc. now owns 9,890,168 shares of the company’s stock worth $469,388,000 after buying an additional 92,034 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Zoetis by 1.9% in the second quarter. Marshall Wace LLP now owns 9,159,978 shares of the company’s stock worth $434,733,000 after buying an additional 173,902 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Zoetis by 114.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,738,248 shares of the company’s stock worth $414,717,000 after buying an additional 4,656,765 shares during the last quarter. Institutional investors and hedge funds own 92.41% of the company’s stock.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) traded up 0.60% during mid-day trading on Tuesday, reaching $50.45. The company’s stock had a trading volume of 2,314,144 shares. Zoetis Inc. has a 52-week low of $38.26 and a 52-week high of $53.14. The stock has a market cap of $24.91 billion, a PE ratio of 36.37 and a beta of 1.05. The company has a 50 day moving average of $50.03 and a 200-day moving average of $49.67.

Zoetis (NYSE:ZTS) last released its earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.06. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. Zoetis’s revenue was up 2.2% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post $1.94 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be issued a dividend of $0.095 per share. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 annualized dividend and a yield of 0.75%. Zoetis’s payout ratio is presently 27.54%.

TRADEMARK VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/29/zoetis-inc-zts-position-boosted-by-delta-lloyd-nv.html.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Monday. Citigroup Inc. raised their price objective on Zoetis from $50.00 to $53.00 and gave the stock a “neutral” rating in a research report on Thursday, August 4th. Barclays PLC raised their price target on Zoetis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 4th. Jefferies Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Zoetis in a research note on Tuesday, August 23rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $58.00 price target on shares of Zoetis in a research note on Wednesday, October 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $55.92.

In related news, insider Heidi C. Chen sold 32,097 shares of the company’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the sale, the insider now owns 46,060 shares in the company, valued at $2,348,138.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kristin C. Peck sold 10,092 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total value of $500,058.60. Following the sale, the insider now owns 22,768 shares in the company, valued at approximately $1,128,154.40. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.